FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression

TITUSVILLE, N.J., February 12, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news